

# Research & Reviews: Journal of Medicinal & Organic Chemistry

## Awareness on Thyroid Cancer

Abhinav Talluri<sup>1\*</sup>, Sunni Talluri<sup>2</sup>

<sup>1</sup>Department of Computer Science, Jawaharlal Nehru Technological University Hyderabad, Nizamabad, Telangana, India

<sup>2</sup>Department of Information Technology, Jawaharlal Nehru Technological University Kakinada, Vijayawada, Andhar Pradesh, India

### Review Article

**Received:** 10/08/2016  
**Accepted:** 12/08/2016  
**Published:** 19/08/2016

#### \*For Correspondence

Abhinav Talluri, Department of Computer Science, Jawaharlal Nehru Technological University, Nizamabad, Telangana.  
E-Mail:  
sunni.talluri@rediffmail.com

**Keywords:** Thyroid cancer, Hormone, endocrinology

#### ABSTRACT

Thyroid growth is the most widely recognized harmful tumor of the endocrine framework. The most successive kind of thyroid danger is papillary carcinoma. These tumors every now and again have hereditary modifications prompting the actuation of the mitogen-activated protein kinase (MAPK) signaling pathway. Most regular changes in papillary carcinomas are point transformations of the BRAF and RAS qualities and RET/PTC revamp. These hereditary modifications are found in >70% of papillary carcinomas and they once in a while cover in the same tumor. Most incessant modifications in follicular carcinomas, the second most basic sort of thyroid danger, incorporate RAS transformations and PAX8-PPAR $\gamma$  revamp. RET point transformations are vital for the improvement of medullary thyroid carcinomas. Large portions of these transformations, especially those prompting the initiation of the MAPK pathway, are as a rule effectively investigated as helpful focuses for thyroid disease. Various mixes have been examined and indicated antitumor impacts in preclinical studies and are being tried in progressing clinical trials.

#### INTRODUCTION

The thyroid gland contains in front of the neck just below the voice box. Thyroid gland made up of two main lobes [right and left] in the middle called the isthmus[1]. Coming to thyroid cancer it is atypical cancer effecting thyroid gland[2].

#### Symptoms

The thyroid cancer is detected when we notice swelling in the neck.

Other symptoms are

- pain in your neck
- difficult to swallow
- Hoarse voice
- Difficult to breathe

#### Types of thyroid cancer

- Papillary
- Follicular

- Medullary
- Anaplastic
- Lymphoma

### ***Papillary***

This type of gland mostly present in the young women more it doesn't mean it can't be found at men, children and old people. It usually seen below the age of 40[3].

### ***Follicular***

It is the common second type which is seen in the older group. It spreads through the lymph glands[4].

### ***Medullary***

It is an uncommon sort which is for the most part found in the families. If this kind of tumor is watched we typically verify whether is the acquired sort so that other relatives can be offer the blood test to check whether they require any therapy or not [5].

### ***Anaplastic***

This is another type of rare cancer which is regularly seen in the older age people. The majority Patients are seen in the 60 years age[6].

### ***Lymphoma***

It is an alternate sort of malignancy which is seen in anyplace in our body as opposed to like the different sorts of thyroid disease and for this medicines will be chemotherapy (drug therapy), monoclonal immune response therapy, radiotherapy[7].

## **Diagnosis**

### ***Starting tests***

#### ***Blood test***

Thyroid functioning test: it Scan the size of thyroid hormones in the blood. It usually tested when the thyroid swells.

#### ***Calcitonin***

The test is basically used to help diagnose cell hyperplasia and medullary thyroid cancer. These usually check in the family members with multiple endocrine neoplasia type 2 (MEN-2)[8-10].

Usually this two types of test are rarely seen in which excessive amount of calcitonin are produced. C-cell hyperplasia is damage condition that may or may not progress to become medullary thyroid cancer. Medullary thyroid cancer is malignant it can spread beyond the thyroid and can be difficult to treat if it is not discovered early[11].

#### ***Fine needle desire cytology***

This test is led with a needle embedded through the skin into the thyroid organ protuberance. It is typically finished with routine center or else it can likewise done through the ultrasound filter. The specimen of cells is then taken a gander at with a magnifying instrument.

#### ***Biopsy***

Once in a while a FNAC result won't be useful and a center biopsy or once in a while a surgical biopsy might be required. In the event that this is required the specialist would clarify in more detail what it would involve and whether any analgesic is required [12,13].

#### ***Thyroid Ultrasound check (USS)***

This test utilizes gel and a test rubbed over the neck to take a gander at the size and surface of the thyroid organ and the lymph organs/hubs in the neck. It can appear if there are any bumps in the thyroid organ, if the protuberances are strong or liquid containing and if the lymph organs/hubs look ordinary fit as a fiddle and size. On

the off chance that anything shows up it is conceivable to utilize the ultrasound test and pictures to manage the needle utilized for a FNA.

## Different examinations/tests

### ***CT (Computerized Tomography) or MRI (Magnetic Resonance Imaging)***

These 2 sorts of sweep demonstrate a 3 dimensional photo of within the body. They are not generally required but rather can be useful to appear if the growth is becoming outside of the thyroid organ and can give more data on the lymph organs/hubs and different parts of the body, for example, the lungs, liver and bones[14].

### ***Thyroid radionucleotide or radioisotope filters***

This test is no more regularly done. It includes an infusion of a little measure of radioactive fluid (either iodine or technetium) into an arm vein took after by a sweep around 20 minutes after the fact. The output pictures are taken utilizing a gamma camera x beam machine which is situated over the neck zone[15,16].

### ***PET (Positron Emission Tomography) filter***

This is another sort of radioactive sweep. It is not all that broadly accessible in the UK as alternate sorts of output examined previously[17-20]. It is once in a while required at the season of thyroid growth conclusion yet may be valuable amid the subsequent time of a little number of patients when other x beam tests have not been useful.

This is utilized to portray the extent of the thyroid malignancy and whether it has spread outside the thyroid organ to include the lymph organs/hubs or different parts of the body [21,22]. Therefor the most part ordinarily utilized arranging framework is called 'TNM'. This stands for Tumor, Nodes and Metastases.

There are 4 T-stages (1-4) and this portrays the extent of the tumor in connection to the thyroid organ.

N portrays whether the disease has spread to the lymph hubs/organs near the thyroid organ.

M depicts whether the growth has spread to different parts of the body, for example, the lungs or bones, to deliver 'secondaries'.

## Surgery

Surgery is normally the primary therapy required for medullary, follicular and papillary thyroid growths. It is unrealistic to be suggested for thyroid lymphoma patients and is just once in a while appropriate for victim with anaplastic thyroid malignancy[22-27]. In the event that thyroid malignancy has been analyzed before surgery it is regular for the entire thyroid organ to be expelled amid the operation (all out thyroidectomy)[28-33]. In the event that there was an trouble diagnosing the explanation behind a thyroid bump or if tumor was not associated Prior to surgery then evacuation with one and only flap of the thyroid might be done (hemithyroidectomy or lobectomy).

On the off chance that stand out projection has been evacuated and after that malignancy is found in it, it is common to examine whether the other thyroid flap should be expelled at a second operation (a consummation thyroidectomy). At times be that as it may (youthful patients with little follicular or papillary tumors) it may be proposed not to expel the rest of the projection.

Once in a while the lymph organs/hubs are likewise evacuated. The amount of organs ousted will depend on upon the size and kind of the threat, what the authority can see and feel at the period of the operation and the eventual outcomes of any yields performed before the operation. Numerous patients can go home 1-3 days after their operation.

In light of where the thyroid organ lies in the neck it is feasible for the accompanying to happen after a thyroid operation:

### ***Raspy Voice***

It happens when the nerve that supplies the vocal strings is "wounded" or harmed amid the operation. The voice changes for this situation are normally make shift. Some of the time the nerve must be sliced so as to get the thyroid organ and the growth out, this is abnormal be that as it may and your specialist will converse with you about any normal dangers previous to the operation.

### ***Minimum calcium levels***

This can occur at the parathyroid organs that sit near the thyroid organ are evacuated or get "wounded" amid the operation[34-38]. These organs control the blood calcium levels. On the off chance that they are not working

typically the calcium level will be low. Later your operation The blood test will be done to check the calcium levels and if the amount are minimum you will be given additional calcium either as a tablet or through a dribble. Your specialist will converse with you about this in more detail.

### ***Thyroxine***

At the point when the thyroid organ is expelled, thyroid hormone solution is expected to supplant the thyroid hormones that the body can no more make[38-45]. Thyroxine tablets should be taken once every day and are generally best taken first thing in the morning.

It may take a short time to get the right measurements for every patient. In any case, once the dosage is sorted you ought to feel your ordinary self as the tablets are supplanting the hormones that your thyroid organ would have delivered. The measurements will be observed by discovering how you feel and by checking blood tests (TFTs).

(On the off chance that you are going to require radioactive iodine therapy you might be put on Tri-iodothyronine tablets to begin with. This is given as a tablet 3 times each day). You should continue with thyroid hormone drug for whatever is left of your life.

On the off chance that you utilize any over the counter wellbeing supplements including multivitamins it merits checking with your specialist whether the season of day you take these tablets should be changed. A few tablets can decrease the measure of thyroxine you can assimilate from you stomach into the circulation system so leaving no less than a 2 hour hole can be useful.

## **Radioactive Iodine Therapy**

### ***RAI Section 1***

This is utilized for Follicular and Papillary thyroid growths. Not all patients with these sorts of thyroid growth will be encouraged to get radioactive iodine therapy. The choice will be made in view of various criteria including tumor size, tumor sort, nearness of tumor outside the thyroid organ, inclusion of lymph hubs, nearness of increases to different parts of the body, quiet age and sexual orientation.

In some generally safe patients it is dubious whether RAI is required and a few patients may in this way be offered the chance to join in the Particle study (Iodine or Not). Additional data can be found on the Clinical Trials pages of this site [45-48].

Like standard iodine in the eating routine, radioactive iodine is taken up by any staying typical thyroid cells and conceivably by thyroid malignancy cells too. The radioactive type of iodine is utilized to pulverize any staying thyroid cells [49-58].

Prior to this therapy can be given, the patient should be arranged so that the therapy stands the most obvious opportunity with regards to working

### ***Get ready for RAI***

#### ***Step 1 - Minimum Iodine Diet***

This is prescribed so as to get as a significant part of the radioactive iodine to the therapy regions of the body and to stop iodine in the eating regimen from meddling with the therapy[58-62]. There is a significant variety in the measure of time that diverse healing centers and specialists propose for the low iodine diet.

You are liable to be solicited to chop down the sum from iodine in your eating regimen for somewhere around 1 and 2 weeks before your therapy. You will have the capacity to eat ordinarily again once the therapy has been done.

The subtle elements of the eating regimen will be given by your own particular healing facility group yet the primary things that contain iodine that you should chop down or maintain a strategic distance from are fish and dairy produce. You may discover case of low iodine diets in booklets and on web destinations that are not intended for the UK populace's eating regimen so it is best to maintain a strategic distance from these as they are unrealistic to be reasonable.

#### ***Step 2 - Delivering an Abnormal state of Thyroid Fortifying Hormone***

There are 2 methods for Obtain this hormone level sufficiently high in the blood to permit the radioactive iodine to do what it needs to do.

The first choice is to stop thyroid hormone medicine and permit the body to make a bigger measure of TSH than common. Numerous individuals battle with this and can create manifestations including tiredness, loss of voracity, weight increase, dry skin, oily hair, obstruction, temperament changes and feeling chilly.

The second choice is to give the TSH in a counterfeit route by infusions (recombinant human TSH, rhTSH, 'Thyrogen'). The infusions are given on the 2 days before the radioactive iodine and are given by infusion into the muscle in the butt cheek. This permits the patient to proceed on their thyroid hormones all through the arrangement and therapy process.

Reactions from rhTSH are phenomenal and by and large gentle. A few people feel debilitated, have a cerebral pain or feel powerless with hurting muscles (like having influenza) after their infusions. This is best dealt with rest, a lot of liquids and paracetamol. A couple people have encountered a rash. rhTSH may not be accessible all over the place and it isn't appropriate for all patients.

## **RAI Part 2**

On the off chance that you are encouraged to have radioactive iodine treatment, this should be as an inpatient in an exceptional work space known as an isotope or seclusion room

.This room is uncommonly adjusted due to the high measurement of radiation required in treatment. Dissimilar to a typical healing facility ward you won't be permitted to have guests in the room. Grown-up guests can visit however should stay in an assigned range outside the room.

You can converse with each other either through a defensive window or perhaps by utilizing a telephone join. You can't have kids to visit.

The treatment measurements of radioactive iodine is generally given as a container to swallow. The container is a comparative size to a paracetamol capsule.

Many patients don't encounter any reactions with radioactive iodine. However the accompanying symptoms can happen dry mouth

- tender or swollen saliva glands
- taste changes
- sore throat
- adjusted sensations around your thyroidectomy scar
- swelling in the thyroid range if a lot of thyroid tissue is still present
- feeling debilitated (despite the fact that this is exceptional)

You will be inquired as to whether you are pregnant before the radioactive iodine case is given to you. In the event that there is any uncertainty then a pregnancy test will be done as the treatment can't proceed on the off chance that you are pregnant. After the radioactive iodine dosage has been given to you, you should void getting to be pregnant for 6 months or abstain from fathering a kid for 4 months.

## **Taking after Radioactive Iodine Treatment**

The treatment will make you radioactive for a timeframe subsequently and along these lines you should stay in the seclusion room whilst the levels of radiation are high. The levels of radiation will be observed whilst you are in the room and once the readings have fallen enough you will be permitted to go home. You will have a full body check utilizing a gamma camera

after the treatment and this is done to see where the radioiodine has gone in the body. On the off chance that you were not as of now on thyroxine before your treatment this should be begun and you are liable to be given a solution to run home with [63-67].

You will at present be radioactive when you go home in this way you will in any case should be cautious what's more, tail a few rules (radiation security measures) keeping in mind the end goal to diminish the dangers to those individuals around you.

Here are a few case of what's in store when you go home:

- rest alone
- attempt to keep more than 6 feet far from other individuals wherever conceivable
- dodge delayed close contact with grown-ups and especially pregnant ladies and kids
- abstain from utilizing open transport and heading off to the silver screen/theater, i.e, places where you
- might be situated alongside the same individual for delayed periods

- flush the can twice
- abstain from getting to be pregnant for 6 months or fathering a tyke for 4 months

The time span that you should take after the direction fluctuates between patients however your doctor's facility will give you exact directions and the date on which you can blend with grown-ups regularly and another date for when you can blend with kids and pregnant or possibly ladies.

On the off chance that you are wanting to go by ship or plane soon after your treatment then it might be prudent to convey a letter expressing that you have as of late gotten radioactive treatment. This is to stay away from any perplexity that might be brought on by delicate radiation recording gadgets at airplane terminals what's more, ship terminals.

### ***Other Radioactive Treatments***

A few patients with medullary thyroid disease might be appropriate for radioactive treatment utilizing distinctive sorts of radioactive concoction. An illustration is mIBG (metaiodobenzylguanidine) treatment.

In spite of the fact that mIBG additionally utilizes radioactive iodine it is altogether different to the treatment clarified above. This treatment is given in the seclusion room yet should be given through a trickle into the circulatory system instead of as a container to swallow.

It is critical to screen pulse readings amid this kind of treatment and to give against infection solution before the treatment begins [68-80]. It is likely that the stay in the seclusion room will be somewhere around 5 and 7 days and again a full body check utilizing a gamma camera will be done a short time later to see where the chemicals have gone in the body. There is no compelling reason to stop thyroid hormones before this kind of treatment. Notwithstanding some different solutions may should be changed or halted before mIBG treatment furthermore, your healing facility group will prompt you on this issue.

### ***Radiotherapy (X-beam Therapy)***

This sort of therapy is not usually utilized as a part of thyroid tumor. It is all the more frequently used to treat Anaplastic and Medullary thyroid growths however can have a part to play in any sort[81-90].

The reasons why this sort of therapy may be offered are:

- radioactive iodine therapy is not appropriate or is not working
- to treat thyroid malignancy cells that couldn't be expelled by surgery
- if an operation is impossible to expel the thyroid organ and thyroid malignancy
- to treat thyroid malignancy that returns after therapy

Radiotherapy includes utilizing capable x beam bars to attempt and murder growth cells whilst permitting the typical cells around the same range to survive.

The therapy is given in a radiotherapy office and the machines are called direct quickening agents or Linacs. Therapy is normally given over a time of a few weeks on a Monday to Friday premise (no therapy at the weekends generally). You might be in the therapy space for a sum of around 20 minutes every day.

It is critical to keep the position of your head and neck as still as could be expected under the circumstances amid therapy so a unique transparent plastic cover is generally made that fits cozily around the state of your face and neck. There are heaps of various sorts of veil yet a case of one of these covers can be seen at

You just wear this whilst you are on the therapy bed. You are dealt with lying on your back. You don't feel anything whilst the x beam bar is exchanged on yet you can for the most part hear the machine working.

The therapy is liable to bring about some reactions. The commonest ones are:

- painful gulping
- dry mouth
- dry, red, excruciating or rankled skin in the locale of the therapy
- altered feeling of taste
- tiredness

- (feeling debilitated/queasiness and balding are not liable to happen)

The symptoms will shift contingent upon precisely what part of the body needs treating and your specialist will clarify in point of interest the possible impacts that you may encounter and whether they are prone to be interim or more enduring.

### ***Chemotherapy (drug therapy)***

This is not generally utilized as a part of thyroid malignancy and accordingly won't be talked about here. For data on particular chemotherapy drugs, please click this connection [81-90].

### ***Radioactive Iodine Therapy***

On the off chance that you have had radioactive iodine therapy for papillary or follicular thyroid disease, you will require a subsequent evaluation between 9-12 months after therapy to check your reaction and to choose if any further radioactive iodine therapy is required.

The subsequent procedure varies marginally yet will include one or a greater amount of the accompanying:

- Thyroglobulin blood test
- Neck ultrasound check
- Radioactive iodine full body check. This is utilized less ordinarily. (Again you should have a high TSH level and will either need to stop thyroid medicine incidentally or have rhTSH infusions. You should take after comparable confinements - including not getting pregnant - to when you had the therapy in the disconnection room [even however this is done as an outpatient] as you will be made radioactive once more.)

Not at all like other more basic tumors, patients with a conclusion of thyroid growth as a rule stay on follow up in the center deep rooted. After the underlying time of therapy and subsequent facility visits, the resulting follow up is frequently just required on an once yearly premise.

Your subsequent facility visits will more often than not include seeing the specialist, having your neck territory inspected; blood tests (e.g. thyroid capacity test (TFT), calcium, thyroglobulin (Tg. To screen papillary and follicular thyroid malignancy), calcitonin and CEA (to screen medullary thyroid tumor) and now and then sweeps.

This is required for various reasons including observing thyroid hormone levels and to check for indications of disease having returned. For a few sorts of thyroid tumor it is workable for malignancy to show itself again numerous years after the fact and that is the reason it is some of the time important to go ahead with follow up for so long.

## **Drug Therapy**

### ***Targeted drug therapy***

Focused on treatment alludes to tranquilize therapies that are made to emerge flawed flagging components in thyroid growth cells. These medications are likewise called tyrosine kinase inhibitors [91-95]. Various distinctive medications have been found in thyroid disease patients with sorts of thyroid tumor. The medications incorporate sorafenib (NexavarR), lenvatinib, vandetanib (CaprelsaR) and cabozantinib. Some of these are presently accessible for use when thyroid disease has spread to different parts of the body, is developing and is connected with troublesome side effects. These medications are not accessible at all spots and are not reasonable for everybody. Your specialist will converse with you about any appropriate alternatives.

## **CONCLUSION**

Thyroid cancer doesn't continuously cause symptoms; usually, the primary sign of thyroid cancer could be a thyroid nodule. Solely regarding 5-17% of thyroid nodules harbour thyroid cancer; most are benign (noncancerous) and cause no issues if left untreated. Many thyroid cancers are noticed within the early stages once patients or their doctors notice nodules in their thyroids either through a physical examination or as associate degree incidental finding on a tomography study. Some doctors counsel you examine your neck rigorously double a year. After your thyroid cancer affected portion has been removed, body can no longer produce the thyroid hormone it needs, so you must take a thyroid hormone pill to produce the natural hormone. Taking thyroid hormone may also help prevent some thyroid cancers from recurring. Long-term management after initial therapy for thyroid cancer varies for each patient. Once therapy is completed, doctor will want to check patient's condition once or twice a year. One might need to go for blood tests between doctor visits to check thyroid

hormone dosage, and if adjustments are needed, one can usually make those without a separate doctor visit. It is better to avoid the risk of getting affected with cancer by taking up following preventive measures.

- Exposure to X-rays may be an established explanation for thyroid cancer, and young kids could also be in danger. Therefore, it would be wise to minimize X-rays in kids.
- In the household salt used contains mostly iodine. However, one would possibly wish to eat a diet that has foods with iodine, comparable to fish, shellfish, eggs, farm product, onions, radishes, potatoes, bananas, parsley and brown algae.
- If the family history shows up cases of medullary thyroid cancer then is better to take a checkup to avoid the disease from building up.

## REFERENCES

1. Fiorentino F, et al. Renal Cell Carcinoma Metastasis to Thyroid Gland Associated with Papillary Thyroid Carcinoma: A Case Report and Review of the Literature. *J Clin Case Rep.* 2016; 6:715.
2. Sarwar R, et al. Association of Promoter Polymorphisms in Xrcc2 Gene Involved in DNA Double Strand Break Repair and Increased Susceptibility to Thyroid Cancer Risk in Pakistani Population. *J Carcinog Mutagen.* 2016; 7: 265.
3. Chen D, et al. Mucinous Micropapillary Carcinoma (Mucinous Carcinomas with Micropapillary Pattern) of the Breast: A Case Report and a Literature Review. *J Clin Case Rep.* 2016; 6:731.
4. Rassman W, et al. Follicular Unit Extraction: Evolution of a Technology. *J Transplant Technol Res* 2016;6:158.
5. Lopes FPPL, et al. Metastatic Medullary Thyroid Cancers: Challenges in Diagnosis with Nuclear Medicine Techniques and the Role of Radionuclide Therapy. *J Nucl Med Radiat Ther.* 2016; S8: S8-001.
6. Blais E, et al. ALK Rearrangement in Anaplastic Thyroid Carcinoma: A Discovery Towards a Personalized Approach?. *J Nucl Med Radiat Ther.* 2016; 7:275.
7. Leidig-Bruckner G, et al. Diagnostic Challenge of Rapid Enlargement of the Thyroid: Autoimmune Thyroiditis - Thyroid Lymphoma - Malignant Thyroid Disease. *Thyroid Disorders Ther.* 2016; 2:128.
8. Abdelghaffar S, et al. Evaluation of Blood Pressure and Left Ventricular Parameters in Children with Classical Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: An Egyptian Experience. *Endocrinol Metab Syndr.* 2016; 4:188.
9. Taira N, et al. Cohort Study of Secondary Endocrine Therapy in Metastatic Breast Cancer with a Poor Response to Initial Endocrine Therapy. *J Clin Trials.* 2016; 6:260.
10. Sasaki K. Duodenal Gastrinoma Associated with Multiple Endocrine Neoplasia Type 1 (MEN1) Detected by Esophagogastroduodenoscopy (EGD), which was buried under Ulcer . *J Gastrointest Dig Syst.* 2016; 6:418.
11. Ticku A and Singh P Metaplastic Carcinoma of Breast with Osteosarcomatous Differentiation: A Rare Case Diagnosed by Fine Needle Aspiration Cytology. *J Med Surg Pathol.* 2016; 1:103.
12. Ramos CO and Mirasol RC Ultrasound Guidance Improves the Diagnostic Yield and Accuracy of Fine Needle Aspiration Biopsy of Thyroid Nodules in Detecting Malignancy. *Thyroid Disorders Ther,* 2014; 3:148.
13. Fan X and Tang Wh Computerized Tomography Scan with a Valsalva Maneuver for the Diagnosis of Denervative Abdominal Wall Hernia. *Surgery Curr Res.* 2016; 5:237.
14. Ramakrishnan VR, et al. Endoscopic Management of Acquired Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine Therapy for Thyroid Malignancy. *J Aller Ther.* 2011; 2:110.
15. Matsubara H, et al. Clinical Outcomes of Conversion Surgery from an External Fixator to an Iodine-Supported Titanium Alloy Plate. *J Microb Biochem Technol.* 2014; 6:049-053.
16. Salih S, et al. The Role of Time to Half-Maximum Activity Clearance of Technetium-99mMercaptoacetyltriglycine in the Assessment of Obstructive Uropathy. *J Nucl Med Radiat Ther.* 2014; 5: 169.
17. Treglia G, et al. Thyroid Incidentaloma at F-18-FDG Positron Emission Tomography: A Challenge for the Clinicians. *Thyroid Disorders Ther.* 2012; 2:e109.

18. Kohler S, et al. Timing of Thyroxine Dose Adjustment in Hypothyroid Patients: When are TSH Levels Stable?. *Thyroid Disorders Ther* 2014; 3: 161.
19. Paul J and Dasgupta S Co-morbidities in Hypothyroid Patients in a Tertiary Health Care Hospital in India. *Thyroid Disorders Ther.* 2012; 1:106.
20. Lambadiari V, et al. Short Term, Low Dose Thyroxin Therapy of Euthyroid Patients with Type 2 Diabetes improves Peripheral Blood Flow and Overall Insulin Sensitivity. *J Diabetes Metab.* 2016; 7:677.
21. Burt A, et al. Tracheal Cyst Presenting as a Potential Recurrent Thyroid Malignancy. *Thyroid Disorders Ther.* 2013; 2:133.
22. Ramakrishnan VR, et al. Endoscopic Management of Acquired Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine Therapy for Thyroid Malignancy. *J Aller Ther.* 2011; 2:110.
23. Leidig-Bruckner G, et al. Diagnostic Challenge of Rapid Enlargement of the Thyroid: Autoimmune Thyroiditis - Thyroid Lymphoma - Malignant Thyroid Disease. *Thyroid Disorders Ther.* 2013; 2:128.
24. Fu WZE, et al. Locally Advanced Anaplastic Thyroid Carcinoma with Long-Term Survival of More Than 7 Years after Combined Surgery Including Tracheal Resection and Radiotherapy: Case Report. *Otolaryngology.*2015; 5: 197.
25. Ionescu L, et al. Anaplastic Thyroid Carcinoma or Thyroid Metastasis from Cholangiocarcinoma? A Case Report. *Journal of Surgery [Jurnalul de chirurgie].* 2015; 11: 77-79.
26. Mato E, et al. Selective Antitumoral Effect of Sorafenib Loaded PLGA Nanoparticles Conjugated with Cetuximab on Undifferentiated/Anaplastic Thyroid Carcinoma Cells. *J Nanomed Nanotechnol.* 2015; 6: 281.
27. Tomisawa Y, et al. Association between Granulocyte Colonies Stimulating Factor (G-CSF) Production and Leukocytosis in Anaplastic Thyroid Carcinoma. *Thyroid Disorders Ther.* 2013; 2: 124.
28. Aricigil M, et al. Sudden Sensorineural Hearing Loss After Total Thyroidectomy Surgery Under General Anesthesia. *Otolaryngol (Sunnyvale).* 2016; 6: 245.
29. Chan TN, Anesthesia Management of Total Thyroidectomy Using a NIM EMG Endotracheal Tube: A Case Report. *J Gen Practice.* 2016; 4: 248.
30. Liu F, et al. Analysis of BRAFV600E Mutation and Persistence of Papillary Thyroid Cancer after Total Thyroidectomy and Routine Central Neck Dissection. *Thyroid Disorders Ther.* 2016; 5:198.
31. Sala DT, et al. "Hungry Bone" Syndrome after Parathyroidectomy: Up-To-Date. *Journal of Surgery [Jurnalul de chirurgie].* 2015; 11: 133-136.
32. Hamour OA, et al. Multiple Rare Complications Following Total Thyroidectomy and Bilateral Neck Dissection: Case Report and Literature Review?. *Endocrinol Metab Syndr.* 2015; 4:209.
33. Vaudrey C, Total Thyroidectomy. *Endocrinol Metab Syndr.* 2015; 4: i010.
34. Qin CD, et al. Surgical Risk after Unilateral Lobectomy versus Total Thyroidectomy: A Review of 47,434 Patients. *Surgery Curr Res.* 2014; 4: 208.
35. Alhefdhi A, Current Concepts in the Presentation, Diagnosis and Management of Primary Hyperparathyroidism. *Journal of Surgery [Jurnalul de chirurgie].* 2015; 11: 1-8.
36. Cho HJ, A Case of Primary Hyperparathyroidism-induced Myoclonic Seizure during the Third Trimester of Pregnancy. *J Preg Child Health.* 2014; 1:104.
37. Spyridon K, et al. Functional Parathyroid Cyst as a Rare Cause of Primary Hyperparathyroidism: A Case Report. *J Arthritis.* 2013; 2: 107.
38. França MM, et al. Spontaneous Remission of Primary Hyperparathyroidism in a Patient with Neurofibromatosis Type 1: Case Report. *J Clin Case Rep.* 2016; 2: 156.
39. Iromo H, et al. Supplementation Doses Thyroxine Hormone of Broodstock Mud Crab (*Scylla serrata*) During Ovarian Maturation. *J Aquac Res Development.* 2015; 6: 379.
40. Zaid FE, et al. Effect of L-Thyroxine Therapy on Musculoskeletal Symptoms of Hypothyroidism. *Rheumatology (Sunnyvale).* 2015; 5: 172.
41. Hariprasad MG, et al. Thyroxine: A Putative Neuroprotectant in Diabetes Induced Peripheral Neuropathy in Rats. *J Diabetes Metab.* 2015; 6: 595.

42. Iromo H, et al. The Optimum Dose of Thyroxine Hormone Supplementation in Broodstock Mud Crab (*Scylla Serrata*) to Accelerate Ovarian Maturation. *J Aquac Res Development*. 2015; 6: 317.
43. Kohler S, et al. Timing of Thyroxine Dose Adjustment in Hypothyroid Patients: When are TSH Levels Stable?. *Thyroid Disorders Ther*. 2014; 3: 161.
44. Kannan S, Effect of Thyroxine on Mosquito Larvae during Winter Months in Dengue Prone Regions of India. *Trop Med Surg*. 2014; 2: 159.
45. Ramakrishnan VR, et al. Endoscopic Management of Acquired Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine Therapy for Thyroid Malignancy. *J Aller Ther*. 2011; 2: 110.
46. Kendi ATK, et al. Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC). *Thyroid Disorders Ther*. 2016; 5: 202.
47. Katoh H, Secondary Thyroid Cancer after Exposure to Radioactive Iodine from the Fukushima Daiichi Nuclear Power Plant accident. *Otolaryngology*. 2012; 2: e104.
48. Asiri MA, Severe Symptomatic Hyponatremia following Low Iodine Diet for Radioactive Iodine-131 Therapy in Patient with Papillary Thyroid Cancer: A Case Report and Review of Literature. *J Nucl Med Radiat Ther*. 2012; S6: 009.
49. Brose MS, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2016; 16: 30166-30168.
50. Touch M, et al. A neural network-based method for spectral distortion correction in photon counting x-ray CT. *Phys Med Biol*. 2016; 61: 6132-6153.
51. Prpic M, et al. Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients. *Head Neck*. 2016; 24:550.
52. Georgiades F, et al. Extensive laryngeal infiltration from a neglected papillary thyroid carcinoma: A case report. *World J Clin Cases*. 2016; 4: 187-190.
53. Kim SH, et al. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-up. *Thyroid*. 2016; 23: 238.
54. Lee KJ, et al. Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy. *Eur J Oncol Nurs*. 2016; 23: 43-50.
55. Sudbrock F, et al. Influence of iodine supply on the radiation-induced DNA-fragmentation. *J Environ Radioact*. 2016; 265: 30239-30249.
56. Banerjee M, et al. Use of imaging tests after primary therapy of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. *BMJ*. 2016; 354: 3839.
57. Liu B, et al. Is post-ablation whole body <sup>131</sup>I scintigraphy still necessary in intermediate-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin < 1 ng/mL? *Clin Endocrinol*. 2016; 13:158.
58. Lee KJ, et al. Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy. *Eur J Oncol Nurs*. 2016; 23: 43-50.
59. Zwarthoed C, et al. Single-photon emission computed tomography for preclinical assessment of thyroid radioiodide uptake following various combinations of preparative measures. *Thyroid*. 2016; 26: 652.
60. Ju DL, et al. Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region. *Nutr Res Pract*. 2016; 10: 167-174.
61. Min H, et al. Effects of Maternal Marginal Iodine Deficiency on Dendritic Morphology in the Hippocampal CA1 Pyramidal Neurons in Rat Offspring. *Neuromolecular Med*. 2016; 18: 203-215.
62. Gandhi A, et al. Lingual Thyroid Ectopia: Diagnostic SPECT/CT Imaging and Radioactive Iodine Therapy. *Thyroid*. 2016; 26: 573-579.
63. Biondi B, et al. Recommendations for therapy of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association. *J Endocrinol Invest*. 2016; 39: 511.

64. Jin HY. Thyroxine binding globulin excess detected by neonatal screening. *Ann Pediatr Endocrinol Metab.* 2016; 21: 105-108.
65. Yeap BB, et al. Reference Ranges for Thyroid-Stimulating Hormone and Free Thyroxine in Older Men: Results From the Health In Men Study. *J Gerontol A Biol Sci Med Sci.* 2016; 132.
66. Durham EL, et al. Effects of thyroxine exposure on the Twist 1 +/- phenotype: A test of gene-environment interaction modeling for craniosynostosis. *Birth Defects Res A Clin Mol Teratol.* 2016; 23543.
67. Virili C, et al. Liquid and softgel levothyroxine use in clinical practice: state of the art. *Endocrine.* 2016; 1035.
68. Gianoukakis AG, et al. Therapy patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer. *Cancer Manag Res.* 2016; 8: 67-76.
69. Costa R, et al. Spotlight on lenvatinib in the therapy of thyroid cancer: patient selection and perspectives. *Drug Des Devel Ther.* 2016; 10: 873-884.
70. Okkalides D. The Result of Multiple I-131 Therapys on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment. *Cancer Biother Radiopharm.* 2016; 31: 58-64.
71. Wolfson RM, et al. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Therapy of Differentiated Thyroid Cancer with Nodal Metastatic Disease. *J Oncol.* 2016; 6496750.
72. Dotan I, et al. Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells. *PLoS One.* 2016; 11: e0149723.
73. Taïeb D, et al. Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study. *Eur J Endocrinol.* 2016; 174: 491-502.
74. Kist JW, et al. 124I PET/CT to Predict the Outcome of Blind 131I Therapy in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). *J Nucl Med.* 2016; 57:701-707.
75. Jin LX and Moley JF. Surgery for lymph node metastases of medullary thyroid carcinoma: A review. *Cancer.* 2016; 122: 358-366.
76. Steinert HC and Aberle S. CME: Radioactive iodine therapy in thyroid cancer. *Praxis.* 2016; 104: 1235-1243.
77. COHEN WD, et al. Effects of estrogen therapy on hormonal functions and serum lipids in men with coronary atherosclerosis. *Circulation.* 1956; 14: 365-372.
78. Querido A, et al. The disappearance rate of thyrotrophic hormone from the bloodstream of normal and thyroidectomized rabbits. *Acta Endocrinol* 1955; 19: 152-156.
79. Myers JD, et al. A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism. *J Clin Invest.* 1950; 29: 1069-1077.
80. Scheinberg P. Cerebral circulation and metabolism in hyperthyroidism. *J Clin Invest.* 1950; 29: 1010-1013.
81. Follin C and Erfurth EM. Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors. *Curr Treat Options Oncol.* 2016; 17: 50.
82. Naddaf SY, et al. Brain-Only Metastases Seen on FDG PET as First Relapse of Papillary Thyroid Carcinoma Two Years Post-Thyroidectomy. *Clin Nucl Med.* 2016; 1035.
83. Navaratne L, et al. The Management of Locally Invasive Primary Thyroid Paraganglioma: A Case Report and Review of the Literature. *Head Neck Pathol.* 2016; 16: 1-7.
84. Compagnon F, et al. Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse *Cancer Radiother.* 2016; 20: 362-369.
85. Scott E, et al. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives. *Future Oncol.* 2016; 0171.
86. Ideguchi M, et al. Metastatic cerebellar tumor of papillary thyroid carcinoma mimicking cerebellar hemangioblastoma. *Springerplus.* 2016; 5: 916.

87. Leo M, et al. Variables Affecting The Long Term Outcome Of Graves' Orbitopathy Following High Dose Intravenous Glucocorticoid Pulse Therapy In Patients Not Treated With Orbital Radiotherapy. *Endocr Pract.* 2016.
88. Käsmann L, et al. Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer. *Anticancer Res.* 2016; 36: 3499-3503.
89. Dabelić N, et al. Primary Fibrosarcoma of the Thyroid Gland: Case Report. 2016; 55: 172-175.
90. Aridome K, et al. A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. *Mol Clin Oncol.* 2016; 4: 393-398.
91. Lin LI, et al. Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature. *Exp Ther Med.* 2016; 11: 201-207.
92. Feng H, et al. Advances in molecular targeted therapy of thyroid carcinoma. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2015; 29: 2188-2190.
93. Kumar M and Awasthi R. Development of Metronidazole-Loaded Colon-Targeted Microparticulate Drug Delivery System. *Polim Med.* 2015; 45: 57-65.
94. Tavarelli M, et al. Hypertrophic Osteoarthropathy and Follicular Thyroid Cancer: A Rare Paraneoplastic Syndrome. *Eur Thyroid J.* 2015; 4: 266-270.
95. Kim Bk, et al. Lower Starting Dose of Sorafenib for Thyroid Cancer : A Case Report and Literature Review. *Thyroid Disorders Ther.* 2015; 4: 196.
96. Cohen MS. The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib. *Chemo Open Access.* 2015; 4: 168.
97. Gheorghisan Galateanu AA, et al. Rectal and Liver Metachronous Cancers and Sorafenib-Induced Thyroid Dysfunction. *J Clin Case Rep.* 2015; 5: 530.
98. Cohen MS. The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib. 2015.
99. Srilatha B, et al. Epidemiology and Therapy for Thyroid Cancer. *J Cancer Sci Ther.* 2011; S17.
100. Hegazy MAF, et al. Unifocal Differentiated Thyroid Cancer Smaller than 1 cm are Better Managed by Total Thyroidectomy. *Surgery.* 2011; 1: 104.